Literature DB >> 15583301

Varicella seroprevalence and molecular epidemiology of varicella-zoster virus in Argentina, 2002.

Gustavo H Dayan1, María S Panero, Roberto Debbag, Ana Urquiza, Marta Molina, Susana Prieto, María Del Carmen Perego, Graciela Scagliotti, Diana Galimberti, Guillermo Carroli, Cristina Wolff, D Scott Schmid, Vladimir Loparev, Dalya Guris, Jane Seward.   

Abstract

There is limited data on immunity against varicella-zoster virus (VZV) in adults in different parts of Argentina, and it is not known which VZV strains are circulating in Argentina. The objectives of this study were as follows: (i) to evaluate seroprevalence of varicella among adults, assessing the accuracy of clinical history and determining the sociodemographic factors associated with seropositivity; and (ii) to determine the VZV strains circulating in Argentina. A cross-sectional serological survey enrolling 2,807 women aged 15 to 49 years attending public health-care settings in four cities in Argentina (i.e., Buenos Aires, Salta, Mendoza, and Rosario) and one rural area was conducted from August to November 2002. Specimens for identification of VZV strains were obtained from vesicular lesions from 13 pediatric patients with varicella from different areas of the country. PCR amplification was used for genotyping. The overall seroprevalence of varicella antibodies was 98.5% (95% confidence interval, 98.0 to 98.9), ranging from 97.2% in central Buenos Aires to 99.3% in southern Buenos Aires and Salta. Varicella seroprevalence increased with age. Crowding and length of residence in the same place were associated with seropositivity. The positive predictive value of varicella history for immunity to varicella was 99.4%; however, the negative predictive value was 2.5%. The European genotype was identified in all viral specimens. In Argentina, seroprevalence in women more than 15 years old was high regardless of the area of residence. Negative or uncertain varicella history was not a good predictor of immunity. VZV genotype was stable in all areas of the country.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583301      PMCID: PMC535276          DOI: 10.1128/JCM.42.12.5698-5704.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Seroprevalence of varicella-zoster virus immunoglobulin G antibodies in Swiss adolescents and risk factor analysis for seronegativity.

Authors:  U Heininger; C Braun-Fahrländer; D Desgrandchamps; J Glaus; L Grize; P Wutzler; U B Schaad
Journal:  Pediatr Infect Dis J       Date:  2001-08       Impact factor: 2.129

2.  Seroepidemiology of varicella-zoster in Pakistan.

Authors:  D S Akram; H Qureshi; A Mahmud; A A Khan; Z Kundi; S Shafi; B Olowokure; J Weil; H Bock; I Yazdani
Journal:  Southeast Asian J Trop Med Public Health       Date:  2000-12       Impact factor: 0.267

3.  Varicella in Americans from NHANES III: implications for control through routine immunization.

Authors:  Paul E Kilgore; Deanna Kruszon-Moran; Jane F Seward; Aisha Jumaan; Frederik P L Van Loon; Bagher Forghani; Geraldine M McQuillan; Melinda Wharton; Laura J Fehrs; Cynthia K Cossen; Stephen C Hadler
Journal:  J Med Virol       Date:  2003       Impact factor: 2.327

4.  Seroprevalence of varicella zoster and rubella antibodies among rural populations of the Chaco region, south-eastern Bolivia.

Authors:  Alessandro Bartoloni; Filippo Bartalesi; Mimmo Roselli; Antonia Mantella; Francesca Dini; Esteban Salazar Carballo; Virgilio Prieto Barron; Franco Paradisi
Journal:  Trop Med Int Health       Date:  2002-06       Impact factor: 2.622

5.  High seroprevalence of antibodies to varicella zoster virus in adult women in a tropical climate.

Authors:  K A O'Grady; A Merianos; M Patel; L Gilbert
Journal:  Trop Med Int Health       Date:  2000-10       Impact factor: 2.622

6.  Susceptibility to varicella-zoster virus among adults at high risk for exposure.

Authors:  S J Alter; J A Hammond; C J McVey; M G Myers
Journal:  Infect Control       Date:  1986-09

7.  Susceptibility to varicella-zoster infection in individuals 1 to 29 years of age in Mexico.

Authors:  M T Alvarez y Muñoz; J Torres; L Damasio-Santana; A Gómez; G Fernández-Quintanilla; R Tapia-Conyer; O Muñoz
Journal:  Arch Med Res       Date:  1999 Jan-Feb       Impact factor: 2.235

Review 8.  Review of varicella zoster seroepidemiology in India and Southeast Asia.

Authors:  B W Lee
Journal:  Trop Med Int Health       Date:  1998-11       Impact factor: 2.622

9.  Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world.

Authors:  P LaRussa; S Steinberg; A Arvin; D Dwyer; M Burgess; M Menegus; K Rekrut; K Yamanishi; A Gershon
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

10.  Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.

Authors:  P LaRussa; O Lungu; I Hardy; A Gershon; S P Steinberg; S Silverstein
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

View more
  10 in total

Review 1.  Epidemiology and factors influencing varicella infections in tropical countries including Sri Lanka.

Authors:  S W P Lakmini Daulagala; Faseeha Noordeen
Journal:  Virusdisease       Date:  2018-07-06

2.  Toward universal varicella-zoster virus (VZV) genotyping: diversity of VZV strains from France and Spain.

Authors:  Vladimir Loparev; Elisa Martro; Elena Rubtcova; Carlos Rodrigo; Jean-Charles Piette; Eric Caumes; Jean-Paul Vernant; D Scott Schmid; Anne-Marie Fillet
Journal:  J Clin Microbiol       Date:  2006-11-29       Impact factor: 5.948

Review 3.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

4.  Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand.

Authors:  Vladimir N Loparev; Elena N Rubtcova; Vanda Bostik; Dhwani Govil; Christopher J Birch; Julian D Druce; D Scott Schmid; Margaret C Croxson
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

5.  Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland.

Authors:  Marjaleena Koskiniemi; Maija Lappalainen; D Scott Schmid; Elena Rubtcova; Vladimir N Loparev
Journal:  Clin Vaccine Immunol       Date:  2007-07-11

6.  Seroprevalence of varicella antibodies among pregnant women in Lyon-France.

Authors:  M Saadatian-Elahi; Y Mekki; C Del Signore; B Lina; T Derrough; E Caulin; J Thierry; P Vanhems
Journal:  Eur J Epidemiol       Date:  2007-05-30       Impact factor: 12.434

7.  Genotypes of clinical varicella-zoster virus isolates from Manaus, Brazil.

Authors:  Michele de Souza Bastos; Jennifer Folster; Otávio Primo de Alvarenga; Daniele de Araujo Sampaio; Ronaldo Marques Pontes Rabelo; Guilherme Augusto Pivoto João; Marcus Vinícius Guimarães de Lacerda; D Scott Schmid
Journal:  Rev Soc Bras Med Trop       Date:  2019-05-16       Impact factor: 2.141

8.  Vaccine Strain and Wild-Type Clades of Varicella-Zoster Virus in Central Nervous System and Non-CNS Disease, New York State, 2004-2019.

Authors:  Patrick Bryant; Tugba Yildirim; Sara B Griesemer; Kara Shaw; Dylan Ehrbar; Kirsten St George
Journal:  J Clin Microbiol       Date:  2022-03-24       Impact factor: 11.677

9.  Burden of varicella in Latin America and the Caribbean: findings from a systematic literature review.

Authors:  Luiza Helena Falleiros Arlant; Maria Catalina Pirez Garcia; Maria L Avila Aguero; Miguel Cashat; Cintia Irene Parellada; Lara J Wolfson
Journal:  BMC Public Health       Date:  2019-05-08       Impact factor: 3.295

10.  Trends in Varicella Burden of Disease Following Introduction of Routine Childhood Varicella Vaccination in Argentina: A 12-Year Time Series Analysis.

Authors:  Norberto Giglio; Pieralessandro Lasalvia; Manjiri Pawaskar; Cintia I Parellada; Yaneth Gil Rojas; Paula Micone; Virginia V Babic; Silvina E Neyro
Journal:  Vaccines (Basel)       Date:  2022-07-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.